Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.40 |
| ▸ | DRD1 | P21728 | 6/20 | 0.40 |
| ▸ | DRD4 | P21917 | 6/20 | 0.40 |
| ▸ | DRD5 | P21918 | 6/20 | 0.40 |
| ▸ | DRD3 | P35462 | 6/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610566 | 0.90 | DRD2 (0.39) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL16610804 | 0.89 | DRD2 (0.42) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL16610582 | 0.88 | DRD2 (0.37) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL16610557 | 0.87 | DRD2 (0.40) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL16610854 | 0.83 | DRD2 (0.38) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL16610999 | 0.80 | DRD2 (0.34) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL16610528 | 0.80 | KDR (0.34) | SCN9A | |
| SCHEMBL16611207 | 0.79 | PRLHR (0.40) | — | |
| SCHEMBL28003808 | 0.78 | DRD2 (0.38) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL16610750 | 0.78 | SCN9A (0.39) | DRD2DRD1DRD4DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | NIPPON SHINYAKU CO., LTD. (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9580413-B2 | Substituted pyrrolidines as ROS tyrosine kinase inhibitors | NIPPON SHINYAKU CO., LTD. (JP) | 2017-02-28 | — | — | US | disclosed |
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2857398-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152095-A1 | AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL | HRH4, CYP3A4, CYP3A5 | DRD2 277/4885DRD1 142/4885DRD4 69/4885 |
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | ROS1, NOX4, NOX3 | DRD2 1196/4885DRD1 876/4885DRD4 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.